FindTrial
Sign In

BBI-825

DRUG2 trials

Sponsors

Boundless Bio, Inc.

Conditions

Anogenital CancerCervical Squamous Cell CarcinomaCutaneous Squamous Cell Carcinoma (CSCC)ER+ Breast CancerHead and Neck (HNSCC)High Grade Endometrial CarcinomaHigh Grade Serous Ovarian CarcinomaLeiomyosarcoma (LMS)

Phase 1

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
TerminatedNCT05827614
Boundless Bio, Inc.Anogenital Cancer, Cervical Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma (CSCC) +9
Start: 2023-03-24End: 2026-03-17Updated: 2026-08-19
Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications
TerminatedNCT06299761
Boundless Bio, Inc.Solid Tumor
Start: 2024-03-28End: 2025-06-25Updated: 2026-06-08

Related Papers

Abstract 6387: Oral and selective ribonucleotide reductase (RNR) inhibitor, BBI-825, suppresses acquired resistance to mutant-specific, pan, and multi-RAS targeting inhibitors
Cancer Research2025-04-21
Preclinical and phase 1/2 data of the CHK1 inhibitor BBI-355 in development for esophageal and gastric cancers (EGC) with <i>EGFR</i> or <i>FGFR2</i> amplifications.
Journal of Clinical Oncology2025-01-272 citations
Abstract 3631: Preclinical and clinical pharmacodynamic characterization of BBI-355, a novel, orally bioavailable, and selective CHK1 inhibitor being evaluated in the first-in-human Phase 1/2 POTENTIATE clinical trial of patients with cancer harboring oncogene amplifications
Cancer Research2024-03-222 citations
Abstract 613: Oral CHK1 inhibitor BBI-355 allows flexibility of dose and schedule with demonstration of monotherapy and combinational antitumor activity in extrachromosomal DNA (ecDNA) driven preclinical models
Cancer Research2024-03-221 citations